Charles Heidelberger, cancer researcher, developed the drug Fluorouracil (5-FU) which is sold under what name?
Charles Heidelberger Charles Heidelberger (December 23, 1920 – January 18, 1983) was a cancer researcher who developed and patented an anticancer drug called 5-Fluorouracil that remains widely used against cancers of the stomach, colon and breast. He was also director of basic research at the University of Southern California's Comprehensive Cancer Center. He received an American Cancer Society National Award in 1974. Heidelberger served on editorial boards of various scientific journals: "Cancer Research", "Molecular Pharmacology", "Biochemical Pharmacology", the "International Journal of Cancer", "In Vitro" , and the "Journal of Medicinal Chemistry".
RS-102221 RS-102221 is a drug developed by Hoffmann–La Roche, which was one of the first compounds discovered that acts as a potent and selective antagonist at the serotonin 5-HT receptor, with around 100x selectivity over the closely related 5-HT and 5-HT receptors. It has anxiolytic effects in animal studies, increases the effectiveness of SSRI antidepressants, and shows a complex interaction with cocaine, increasing some effects but decreasing others, reflecting a role for the 5-HT receptor in regulation of the dopamine signalling system in the brain.